Subsequently, nivolumab, another anti-PD-1 antibody, showed significant OS improvement in patients with metastatic ESCC after ≥1 prior line of systemic therapy (regardless of PD-L1 status) [6]. The gene discussed is CD274; the disease is esophageal squamous cell carcinoma.